| Document |
Document Title |
|
WO/2017/007790A9 |
The present invention relates to compounds according to Formula (I) or Formula (II), which are potential bone imaging agents and therapeutic agents for treating bone tumors and metastases. Certain compounds labeled with 68Ga displayed ex...
|
|
WO/2018/005591A1 |
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...
|
|
WO/2018/004338A1 |
Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by ...
|
|
WO/2017/218344A1 |
Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A...
|
|
WO/2017/195149A1 |
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
|
|
WO/2017/192304A1 |
The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic di...
|
|
WO/2017/191619A2 |
The present invention provides a process for the preparation of a salt of sacubitril and valsartan. Specifically, the present invention provides a process for the preparation of a sodium salt of sacubitril and valsartan.
|
|
WO/2017/188551A1 |
The present invention relates to a novel N-acylurea derivative and use thereof in the treatment or prevention of cardiovascular diseases and, more particularly, to a novel N-acylurea derivative, a pharmaceutical composition comprising th...
|
|
WO/2017/189692A1 |
The invention described herein relates to methods for treating cancer in a subject by administering an effective amount of a CXCL12 signaling inhibitor and a subtherapeutic amount of an anti-cancer agent, e.g., a chemotherapeutic agent.
|
|
WO/2017/180323A1 |
The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide re...
|
|
WO/2017/178301A1 |
The present invention relates to new class of functionalized polyazamacrocycles including at least one phosphonic or phosphinic group linked to a nitrogen atom of the macrocyclic cage, and capable of chelating paramagnetic metal ions, th...
|
|
WO/2017/177004A1 |
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...
|
|
WO/2017/168451A1 |
The present invention provides derivatives of imidazole and benzimidazole based thiones and selones used for degrading various toxic heavy metal and salts thereof to a less toxic, stable and insoluble form. The present invention also pro...
|
|
WO/2017/165473A1 |
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
|
|
WO/2017/165558A1 |
The invention provides compounds, compositions, and methods for treating pain.
|
|
WO/2017/161356A1 |
Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeuti...
|
|
WO/2017/153235A1 |
The invention relates to novel substituted N-cyclo-3-aryl-1-naphthamide derivatives, to methods for producing same, to the use thereof, either alone or in combination, for the treatment and/or prevention of diseases, and to their use for...
|
|
WO/2017/154991A1 |
[Problem] To provide a novel temperature-responsive compound which exhibits a good self-assembling function. [Solution] A temperature-responsive compound represented by formula (1) [wherein R's independently represent a group represented...
|
|
WO/2017/142221A1 |
The present invention relates to a novel preparation method for tri-tertiary-butyl-2,2',2''-(1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetate and, more particularly, to a method for synthesizing tri-tertiary-butyl-2,2',2''-(1,4,7,1...
|
|
WO/2017/137770A1 |
According to the invention there is provided acompound of formula I, wherein R1 and R2 have meanings given in the description,which compounds are useful in the treatment of skin disorders and other diseases.
|
|
WO/2017/136589A1 |
Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of ...
|
|
WO/2017/131213A1 |
Provided is a method for producing, at a high yield, a 1H-tetrazole derivative using a flow reactor and using an azide compound and a cyanide compound as starting materials. The method of producing a 1H-tetrazole derivative of the presen...
|
|
WO/2017/124835A1 |
The present invention discloses a compound (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compound of the present invention provides excellent interference of a binding of NRF2 by KEAP...
|
|
WO/2017/122209A2 |
Disclosed herein are compounds capable of inhibiting dimerization of NF-κB, for example, p65-p65 homodimerization and/or p50-p65 heterodimerization, the compounds being represented by formula I: X-L2-L1-L'2-Y Formula I wherein X, Y, L1,...
|
|
WO/2017/106427A1 |
A method for catalytically converting a dihydrotetrazine 1 into a tetrazine 2, wherein one R group on the dihydrotetrazine 1 is a substituted or unsubstituted aryi, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, or heteroatom-containing ...
|
|
WO/2017/106253A1 |
Conformationally strained irans-cycloalkenes and derivatives thereof suitable for radiolabeling in a subject in need thereof.
|
|
WO/2017/102275A1 |
The invention relates to a compound of formula (I), an N-oxide or an agriculturally suitable salt thereof, wherein the variables are as defined in the specification, and their use as herbicides.
|
|
WO/2017/103258A1 |
The present invention provides methods for the preparation of compounds useful in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,...
|
|
WO/2017/097085A1 |
Disclosed is a preparation method for a eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt, comprising: firstly, obtaining a clear solution of an AHU-377 and diovan trisodium salt compound, a solvent of the clear solut...
|
|
WO/2017/098038A1 |
The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Re...
|
|
WO/2017/099530A1 |
Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency und...
|
|
WO/2017/096772A1 |
Disclosed is a method for preparing an anti-heart-failure medicine LCZ696. The preparing method comprises the following steps (formula (I)): in an organic solvent, a sacubitril dicyclohexylamine salt reacts with valsartan under the effec...
|
|
WO/2017/098044A1 |
The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance...
|
|
WO/2017/093351A1 |
The invention relates to the provision of novel inhibitors for the cytosolic phospholipases A2, the inhibitors having a special metabolization stability.
|
|
WO/2017/093263A1 |
The present invention relates to a process for the synthesis of 3,6 functionalized 1,2,4,5-tetrazine compounds of formula (I); wherein A and B being the same; and wherein at least one of R1, R1', R2 and R2' and at least one of R10 and R1...
|
|
WO/2017/091041A1 |
The present invention provides: a novel salt of Fimasartan having excellent solubility, bioavailability, and physicochemical properties; a method for preparing the same; and a pharmaceutical composition containing the same.
|
|
WO/2017/080443A1 |
A class of compounds of monosulfonic phenyltetrazole, with the structure of 2- (R1 phenyl) -5 (2-sulfonic phenyl) -2H-tetrazole. The 2-sulfonic phenyl tetrazolium salt of this invention has advantages of low toxicity, short synthetic rou...
|
|
WO/2017/082620A1 |
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound containing the same, and a pharmaceutical composition containing the same as an active ingredient...
|
|
WO/2017/080290A1 |
Provided a complex of formula is [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)
propionate- (S)-3'-methyl-2'- (pentanoyl {2''-(tetrazol-5-ylate) biphenyl-4'-ylmethyl}amino) butyrate] 6·XCa2+·YNa+·ZH2O, wherein ...
|
|
WO/2017/055146A1 |
Described are acylated N-(1,2,5-oxadiazole-3-yl)-, N-(1,3,4-oxadiazole-2-yl)-, N-(tetrazole-5-yl)- and N-(triazole-5-yl)-aryl carboxamides of formula (I) and the use thereof as herbicides. In said formula (I), R, V, X, Y, and Z are group...
|
|
WO/2017/059303A1 |
Provided herein are vinylogous thioester compounds and methods for using the compounds.
|
|
WO/2017/053564A1 |
An especially robust compound and its derivative metal complexes that are approximately one hundred-fold superior in catalytic performance to the previously invented TAML analogs is provided having the formula (I) wherein Y1, Y2, Y3 and ...
|
|
WO/2017/049096A1 |
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, and/or a compound of 14 or 14*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to prov...
|
|
WO/2017/049080A1 |
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7, 7* and ...
|
|
WO/2017/037596A1 |
The present application relates to amorphous solid dispersion of LCZ-696 with one or more pharmaceutically acceptable carrier. Specifically, the present application relates to amorphous solid dispersion of LCZ-696 with one or more pharma...
|
|
WO/2017/037639A1 |
The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of ex...
|
|
WO/2017/037591A1 |
The present invention relates to a process for preparing amorphous form of Sacubitril / Valsartan sodium salt of Formula-II and pharmaceutical composition comprising thereof.
|
|
WO/2017/032728A1 |
The invention relates to substituted ketoxime benzoylamides of general formula (I) as herbicides. In said formula (I), R1', R2', X, Y and W represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen...
|
|
WO/2017/020841A1 |
Disclosed is a pharmaceutical composition containing a specific crystalline powder of LCZ696. The crystalline powder of LCZ696 having a specific powdery feature satisfies a requirement of a preparation process and can be used to produce ...
|
|
WO/2017/012917A1 |
Several methods for the preparation of an amorphous powder comprising a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions c...
|
